All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Martin Dreyling
Executive Steering Committee Member
Professor Martin Dreyling is Professor of Medicine and Head of the lymphoma program in Medical Clinic III, Groβhadern Clinic, Ludwig-Maximilians-Universität, Munich, DE. He studied at the universities of Düsseldorf, Giessen, Tübingen, and Würzburg, DE, and completed his clinical training at the universities of Bonn, Münster, Göttingen, and Munich, DE. In addition, he was Visiting Scientist at the University of Chicago, US, between 1992−1995.
His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation, and secondary genetic alterations, as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including novel antibodies and molecular targeted approaches, like inhibitors of the B-cell receptor pathway.
Prof. Dreyling is Coordinator of the European MCL Network and Assistant Coordinator of the German Low-Grade Lymphoma Study Group. He has co-authored numerous scientific papers, book chapters, and abstracts in international peer-reviewed journals.
Positions of responsibility/awards:
- Coordinator of the European MCL Network since 2003
- On the advisory board for the German Society for Hematology and Medical Oncology (DGHO) from 2004–2017
- On the board of the German Study Group for Low-grade Malignant Lymphomas (GLSG) since 2002
- Coordinator of the Center for Malignant Hematology (HaemaKUM) since 2012
- Received the Ellen Glesby Leadership Award, 2007
- Received the Fritz Acker prize, 2015
- Received the Hermansky Award for Hematology Oncology, 2017
Filter by content: